Oncorus (Oncorus) Shares Outstanding (Basic Average) : 26.10 Mil (As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Oncorus Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Oncorus's average basic shares outstanding for the quarter that ended in Mar. 2023 was 26.10 Mil.

Oncorus Shares Outstanding (Basic Average) Historical Data

The historical data trend for Oncorus's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncorus Shares Outstanding (Basic Average) Chart

Oncorus Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Shares Outstanding (Basic Average)

9.16

12.50

6.08

25.32

25.92

Oncorus Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Shares Outstanding (Basic Average)	Get a 7-Day Free Trial												25.87	25.88	25.97	25.98	26.10

Oncorus Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Oncorus (OTCPK:ONCR) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Oncorus Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Oncorus's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncorus (Oncorus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » Shares Outstanding (Basic Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Corporate Drive, Andover, MA, USA, 01810

Website

https://www.oncorus.com

Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.

Executives

Brian J. Shea	officer: Interim CEO	C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte	officer: Interim CFO	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn	director, 10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough	director	C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall	officer: CFO and Treasurer	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin	officer: COO and Chief of Staff	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin	director	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva	officer: CSO and SVP, Research	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116